Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH701Q)

Drug Name
CFI-402257 Drug Info
Synonyms
1610759-22-2; CHEMBL4442392; CHEMBL4469414; SCHEMBL16729234; SCHEMBL17182976; SCHEMBL17190272; SCHEMBL22046104; SCHEMBL22875551; BCP31204; EX-A2577; BDBM50512456; BDBM50533120; NSC800888; ZINC669678971; CS-6527; NSC-800888; SB19839; AK685452; HY-101340; CFI 402257; CFI402257; J3.619.525H; 1610677-37-6; N-cyclopropyl-4-(7-((((1r,3r)-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(pyridin-3-yloxy)pyrazolo[1,5-a]pyrimidin-3-yl)-2-methylbenzamide; N-cyclopropyl-4-[7-[(3-hydroxy-3-methylcyclobutyl)methylamino]-5-pyridin-3-yloxypyrazolo[1,5-a]pyrimidin-3-yl]-2-methylbenzamide
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
118086034
TTD Drug ID
DMH701Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Dual specificity protein kinase TTK (MPS1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BOS172722 DMU790L Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
BAY1161909 DMUK6YM Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
Tricyclic isoxazoloquinazoline derivative 2 DMH4TY1 N. A. N. A. Patented [5]
Tricyclic isoxazoloquinazoline derivative 4 DM8VIM4 N. A. N. A. Patented [5]
Tricyclic isoxazoloquinazoline derivative 3 DML2PWF N. A. N. A. Patented [5]
2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One DMDN12L Discovery agent N.A. Investigative [6]
GNE-7915 DMYWM56 Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dual specificity protein kinase TTK (MPS1) TTP7EGM TTK_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT02792465) A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2 Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 National Cancer Institute Drug Dictionary (drug id 761238).
5 Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
6 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7 Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2014 Feb 13;57(3):921-36.